Active — Not RecruitingNot Applicable

Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia

South Korea4,000 participantsStarted 2022-06-20

Plain-language summary

This study is a large-scale, prospective, multi-center, and non-interventional observation study to observe blood pressure and blood lipid changes and safety during administration of olomax tablets for 24 weeks in hypertensive patients with dyslipidemia.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult aged 19 or older at the time of the baseline visit.
✓. A patient with hypertension and dyslipidemia who is scheduled to administer olomax tablet according to investigator's medical judgement.
✓. A person who can understand the information provided to him/her and may voluntarily sign a written consent form

Exclusion criteria

✕. A person who falls under the prohibition of administration according to the permission for olomax tablet
✕. A person who has a history of administering olomax tablets before participating in this study
✕. In addition to the above, a person that the investigator thinks he/she is not suitable for participating in this observation study;

What they're measuring

The rate of change in LDL-C

Timeframe: at 24 weeks

The amount of change in LDL-C

Timeframe: at 24 weeks

Trial details

NCT IDNCT05660135

SponsorDaewoong Pharmaceutical Co. LTD.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-11-30

View on ClinicalTrials.gov More Hypertension trials